- ￥680 - 29980
- Sino Biological
- 北京
- 11066-HNAH
- 2026年01月26日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20℃ to -80℃
- 保质期：
12个月
- 英文名：
Recombinant Human / Cynomolgus VEGF / VEGFA Protein
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 规格：
1.00 mg/5.00 µg/20.00 µg/100.00 µg/500.00 µg
| 规格： | 1.00 mg | 产品价格： | ￥29980.0 |
|---|---|---|---|
| 规格： | 5.00 µg | 产品价格： | ￥680.0 |
| 规格： | 20.00 µg | 产品价格： | ￥2480.0 |
| 规格： | 100.00 µg | 产品价格： | ￥4980.0 |
| 规格： | 500.00 µg | 产品价格： | ￥12880.0 |
蛋白名称：Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein
蛋白构建：A DNA sequence encoding the human / cynomolgus VEGF165 isoform (P15692-4) (Met1-Arg191) was expressed. Human and Cynomolgus VEGF165 sequences are identical.
表达宿主：HEK293 Cells
蛋白纯度：> 95 % as determined by SDS-PAGE
蛋白活性：1. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 2-10 ng/mL. 2. Labeled biotin to VEGF165 Protein, Human / Cynomolgus, Recombinant by a certain molar ratio; Using the Octet RED System, the affinity constant (Kd) of VEGF165 Protein, Human / Cynomolgus, Recombinant, Biotinylated(Cat:11066-HNAH-B) bound to Avastin was 0.1 nM.
蛋白内毒素：< 1.0 EU per μg of the protein as determined by the LAL method
预测N端：Ala 27
蛋白分子量：The recombinant human / cynomolgus VEGF165 consists of 165 amino acids and predicts a molecular mass of 19.2 KDa. It migrates as an approximately 20 and 22 KDa band in SDS-PAGE under reducing conditions due to different glycosylation.
蛋白NP号：P15692-4
蛋白氨基酸序列：Met1-Arg191
蛋白标签：Native
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验2, Zhao, W; et al. Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition. Cell research, PMID: 31501519
3, Chen, X; et al. Integrative epigenomic and transcriptomic analysis reveals the requirement of JUNB for hematopoietic fate induction. Nature communications, PMID: 35668082
4, Wu, X; et al. Rapid conversion of porcine pluripotent stem cells into macrophages with chemically defined conditions. The Journal of biological chemistry, PMID: 38097188
5, Maji, D; et al. Enhancing In Vivo Electroporation Efficiency through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies. Pharmaceutics, PMID: 38675208
6, Lee, Y; et al. Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models. Ophthalmology and therapy, PMID: 38907092
7, Pan, Z; et al. Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery. Cell stem cell, PMID: 39579761
8, Wang, S; et al. Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein. International journal of biological macromolecules, PMID: 40730308
9, Zhang, Z; et al. Galectin-3-integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodents. Nature communications, PMID: 40775187
10, Liu, C; et al. Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, PMID: 40939487
11, Cai, Y; et al. G6PD deficiency is implicated in Circle of Willis variants in stroke patients and impairs brain vasculature in zebrafish. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, PMID: 40995861 1
2, Xing, Y; et al. Glycosylation-enabled chemoselective growth factor engineering for biomaterial functionalization. Acta biomaterialia, PMID: 41043672 1
3, Xia, N; et al. Niche Environment Remodeling Promotes Long-Term Endometrium Stromal Stem Cell Engraftment and Tissue Regeneration in Thin Endometrium. Molecular therapy : the journal of the American Society of Gene Therapy, PMID: 41176621
X性联无丙种球蛋白血症(X-linked agammagl，bulinemia，XLA)是临床上首次确定的体液免疫缺陷病，由Brutor于1952年报道，故又称Bruton病。XLA作为常见的原发性免疫缺陷病之一，特点为血清中各类免疫球蛋白缺乏，或只能测得微量的抗体。外周血和淋巴组织中B细胞减少或完全缺乏，淋巴结中无生发中心和浆细胞。本病起病早，在出生数月后当患儿体内的母源性抗体水平下降时开始发病。临床表现为反复化脓性感染，患者细胞免疫功能不受影响(部分患者有T细胞数量减少)，主要缺陷
在人细胞中快速、高水平地表达目的蛋白 在2至3个星期内即可获得高效价的病毒 无需噬斑纯化 靶细胞可以是分裂或不分裂的细胞（dividing/or nondividing cell） CLONTECH的Adeno-X™表达系统是一个特别 高效的腺病毒表达系统，用于在人细胞中瞬时及高水平地表达目的蛋白质。由于Adeno-X™病毒DNA中含有特别设计的克隆位点，你可以在2星期内获得高效价的腺病毒，其效率远高于其他腺病毒系统。 高效表达目的蛋白
X伴性显性遗传病（X－linked dominant inheritable disease）
性肾炎（hereditary nephritis）儿时多仅为无症状蛋白尿或反复发作的血尿（有些病例可为肉眼血尿），较少有高血压。但病情持续缓慢地进展，男性到青壮年期常死于慢性肾功能衰竭；女性病情较轻，可达到正常寿限，但偶尔也有个别患者发展到尿毒症者。 有的患者有神经性耳聋；有的患者眼异常，如白内障、近视或锥形晶体、锥形角膜、眼球震颤和球形晶体等。致病基因位于Xq21.3～q24。不过遗传性肾炎存在遗传异质性，即也有常染色体显性遗传和常染色体隐性遗传。 2.假肥大
技术资料暂无技术资料 索取技术资料
